{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:15:54Z","timestamp":1789197354072,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018439","name":"SK Life Science Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018439","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eplepsyres.2026.107869","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:20:20Z","timestamp":1783437620000},"page":"107869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Carisbamate treatment of adult and pediatric patients with Lennox-Gastaut syndrome: A phase 1 pharmacokinetic, safety, and tolerability study"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2917-0369","authenticated-orcid":false,"given":"Vijay","family":"Vashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Kamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Vossler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eplepsyres.2026.107869_bib1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10072-017-3188-y","article-title":"Lennox-Gastaut syndrome: a comprehensive review","volume":"39","author":"Asadi-Pooya","year":"2018","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.eplepsyres.2026.107869_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurol.2020.01.364","article-title":"Lennox-Gastaut syndrome: new treatments and treatments under investigation","author":"Auvin","year":"2020","journal-title":"Rev. Neurol. (Paris. )"},{"issue":"3","key":"10.1016\/j.eplepsyres.2026.107869_bib3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bcp.12267","article-title":"Paediatric pharmacokinetics: key considerations","volume":"79","author":"Batchelor","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2-3","key":"10.1016\/j.eplepsyres.2026.107869_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eplepsyres.2010.09.001","article-title":"Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X)","volume":"92","author":"Bialer","year":"2010","journal-title":"Epilepsy Res."},{"issue":"2","key":"10.1016\/j.eplepsyres.2026.107869_bib5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/clpt.1991.117","article-title":"Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine","volume":"50","author":"Crom","year":"1991","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2-3","key":"10.1016\/j.eplepsyres.2026.107869_bib6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.eplepsyres.2008.01.002","article-title":"The novel antiepileptic drug carisbamate (RWJ 333369) is effective in inhibiting spontaneous recurrent seizure discharges and blocking sustained repetitive firing in cultured hippocampal neurons","volume":"79","author":"Deshpande","year":"2008","journal-title":"Epilepsy Res."},{"issue":"20","key":"10.1016\/j.eplepsyres.2026.107869_bib7","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1212\/01.wnl.0000334751.89859.7f","article-title":"Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures","volume":"71","author":"Faught","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.eplepsyres.2026.107869_bib8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1528-1167.2007.01278.x","article-title":"Effects of carisbamate (RWJ-333369) in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS","volume":"49","author":"Fran\u00e7ois","year":"2008","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.eplepsyres.2026.107869_bib9","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1111\/j.1528-1167.2008.01657.x","article-title":"A new potential AED, carisbamate, substantially reduces spontaneous motor seizures in rats with kainate-induced epilepsy","volume":"49","author":"Grabenstatter","year":"2008","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.eplepsyres.2026.107869_bib10","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1528-1167.2010.02960.x","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures","volume":"52","author":"Halford","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2026.107869_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1159067","article-title":"Concerted suppressive effects of carisbamate, an anti-epileptic alkyl-carbamate drug, on voltage-gated Na(+) and hyperpolarization-activated cation currents","volume":"17","author":"Hung","year":"2023","journal-title":"Front. Cell. Neurosci."},{"issue":"6","key":"10.1016\/j.eplepsyres.2026.107869_bib12","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamaneurol.2022.0829","article-title":"Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial","volume":"79","author":"Knupp","year":"2022","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107869_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.eplepsyres.2007.12.013","article-title":"Pharmacokinetics, safety, and tolerability of the new antiepileptic carisbamate in the elderly","volume":"79","author":"Levy","year":"2008","journal-title":"Epilepsy Res."},{"issue":"12","key":"10.1016\/j.eplepsyres.2026.107869_bib14","article-title":"Carisbamate add-on therapy for drug-resistant partial epilepsy","volume":"12","author":"Lu","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107869_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.nurt.2006.11.016","article-title":"Carisbamate (RWJ-333369)","volume":"4","author":"Novak","year":"2007","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.eplepsyres.2026.107869_bib16","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.eplepsyres.2026.107869_bib17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1528-1167.2009.02318.x","article-title":"Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trials","volume":"51","author":"Sperling","year":"2010","journal-title":"Epilepsia"},{"issue":"2-3","key":"10.1016\/j.eplepsyres.2026.107869_bib18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.eplepsyres.2007.03.012","article-title":"Evaluation of carisbamate, a novel antiepileptic drug, in photosensitive patients: an exploratory, placebo-controlled study","volume":"74","author":"Trenit\u00e9","year":"2007","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2026.107869_bib19","unstructured":"US Food and Drug Administration, 2017. Orphan drug designations and approvals: carisbamate. \u3008https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=594117\u3009 (accessed August 8 2025)."},{"issue":"Pt A","key":"10.1016\/j.eplepsyres.2026.107869_bib20","article-title":"Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice","volume":"104","author":"Verrotti","year":"2020","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2026.107869_bib21","article-title":"American Epilepsy Society Treatments Committee","author":"Vossler","year":"2024","journal-title":"A summary of antiseizure medications available in the United States. 4th Ed."},{"issue":"11","key":"10.1016\/j.eplepsyres.2026.107869_bib22","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1111\/j.1528-1167.2006.00814.x","article-title":"Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans","volume":"47","author":"Yao","year":"2006","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.eplepsyres.2026.107869_bib23","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1111\/j.1528-1167.2009.02081.x","article-title":"Pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western subjects","volume":"50","author":"Zannikos","year":"2009","journal-title":"Epilepsia"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121126001397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121126001397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:48:57Z","timestamp":1789195737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121126001397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"alternative-id":["S0920121126001397"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2026.107869","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carisbamate treatment of adult and pediatric patients with Lennox-Gastaut syndrome: A phase 1 pharmacokinetic, safety, and tolerability study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2026.107869","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107869"}}